Medical Analysis

Components Blood

By: Dr. Dipak Ladda, M.D.

Introduction

Various components of blood like red cells, platelets and plasma can be separated from one another by centrifugation because of their different specific gravities. This mechanical fractionation allows each fractionated blood component to be isolated and utilized for precise medical interventions and targeted transfusion protocols.

Components of Blood

Know Blood Components and Importance

Understanding the distinct functional and structural variations among separate blood components is essential to evaluating their individual therapeutic roles and medical importance within the human system.

BLOOD COMPONENTS

The initial processing of raw biological material begins with Whole Blood. When subjected to specific laboratory protocols, it undergoes a light spin or a heavy spin to facilitate precise element isolation. Utilizing a light spin step yields platelet-rich plasma (PRP) and packed cell volume (PCV). Applying a heavy spin step splits the material to isolate platelet-poor plasma (PPP) alongside the packed cell volume (PCV) matrix. Following further processing, the platelet-rich plasma (PRP) fraction undergoes an additional light spin sequence to yield fresh frozen plasma (FFP) and specialized platelet concentrate (PC) units.

Components of Blood

The comprehensive structural taxonomy of human blood material is systematically cataloged into distinct sub-types:

• Cellular Components: This category comprises red cell concentrate (RCC), Granulocytes, and platelet concentrate (PC) fractions.

• Plasma Components: This essential category consists of fresh frozen plasma (FFP), platelet-rich plasma (PRP), cryoprecipitate complexes, and single donor plasma (SDP) configurations.

• Plasma Derivatives: This fraction contains 5% & 25% albumin formulations, plasma protein fraction products, isolated factor VIII complexes, raw fibrinogen components, protective immunoglobulin preparations, and other coagulation factors.

Whole Blood

The primary physical characteristics of this unseparated biological material include a baseline combination of functional RBCs & plasma. Notably, delicate structures like WBC and Platelets are not viable after 24 hours of standard processing. The standard clinical shelf life is highly dependent on the preserving anticoagulant solutions utilized: storing the unit in ACD or CPD provides a shelf life of 21 days, whereas storing the unit in CPDA1 extends the overall shelf life to 35 days. The mandated storage conditions require continuous preservation at stable temperatures between 2-4°C. A standard collected unit maintains an average total volume of 350-450 ml. The core medical indications for prescribing this transfusion material include severe anemia to reduce chances of circulatory overload.

PCV

The definitive physical characteristics of packed cell volume (PCV) center around concentrated RBCs & a significantly reduced plasma volume. Just as with unseparated material, the structural WBC and platelets are not viable after 24 hours of isolation. The therapeutic shelf life matches standard cell parameters, showing a shelf life of 21 days in ACD or CPD, and up to 35 days when preserved in CPDA1. The authorized storage conditions necessitate maintaining the cells at 2-4°C. A single prepared unit typically encompasses a volume of 200-300 ml. The primary medical indications for administering PCV include hemolytic anemia especially in aplastic crisis, various hypoplastic anemias, various aplastic anemias, and severe anemia accompanying chronic renal disease.

Fresh Frozen Plasma

The specific physiological characteristics of Fresh Frozen Plasma (FFP) encompass a rich mixture of essential plasma proteins, vital coagulation factors, and active complement complexes. The baseline shelf life permits usage up to 5 days, at with constant agitation. The strict storage conditions demand freezing the product at temperatures of <-18°C and ensuring clinical staff use immediately after thawing to avoid protein degradation. A single unit provides a standard volume of 200-260 ml. Regarding the downstream dosage effect, 1 ml of FFP has 100% coagulation activity. The critical medical indications for utilizing FFP include the rapid reversal of coumarin drug effect, direct use in Antithrombin deficiency, and managing complex immunodeficiency syndromes. It is also indicated in open heart surgery and for managing multiple coagulation factor deficiencies in bleeding patient secondary to liver disease, DIC, and dilutional changes from massive blood transfusion.

Random Donor Platelet Concentrate

The biological characteristics of a Random Donor Platelet Concentrate consist of a high concentration of platelets totaling 5.5 x 10^10, some WBCs (specifically Lymphocytes), and approximately 50 ml plasma. The preparation sequence requires executing a low spin PRP step, followed by a high spin PC step with 50 ml plasma. This product must be successfully made from whole blood within 6-8 hours of initial collection. It features a shelf life of 5 days, with constant agitation. The mandatory storage conditions require keeping the units at room temperature ambient values of 20-24°C. The standard volume of a prepared unit is 50 ml. The targeted therapeutic dosage effect yields a systemic increase of 5000-10000/cu. mm. in the patient’s circulating count. The definitive medical indications for this product include severe thrombocytopenia due to a decreased rate of platelet production as in leukemia, hypoplastic anaemia, chemotherapy and radiation induced hypoplasia, disseminated intravascular coagulation (DIC), functional platelet abnormalities, and severe viral disease eg. Dengue.

Single Donor Platelet Concentrate

The distinct characteristics of a Single Donor Platelet Concentrate include an increased concentration of platelets reaching 3 x 10^11, a few WBCs (specifically Lymphocytes), a larger volume of 250 ml plasma, and a few RBCs. This highly concentrated therapeutic option is made from whole blood within 6-8 hours of standard collection. It maintains a shelf life of 5 days, at with constant agitation. The approved storage conditions necessitate holding the product at 20-24°C. A single prepared unit yields a total volume of 250-350 ml. The enhanced therapeutic dosage effect provides an increase of 30000-60000/cu. mm. within the bloodstream. The core medical indications for selecting a single donor unit include active sepsis and treating severely granulocytopenic patients (WBC < 500/µl) who remain completely unresponsive to 48 hours third generation antibiotics therapy.

Cryoprecipitate

The detailed chemical characteristics of cryoprecipitate focus on an isolated concentration of Factor VIII, fibrinogen, Wvf, Factor XIII, and fibronectin. It features an extended shelf life of 1 year. The preparation protocol states that it is produced by slowly thawing a unit of FFP at 1°-6°C leaving a small amount of cryo precipitate. The strict storage conditions mandate keeping the compound at <-18°C and ensuring clinicians use immediately after thawing at 37°C. A single unit provides a small volume of 10-15 ml. Regarding its comparative dosage effect, 1 ml of FFP has 100% coagulation activity. The primary clinical indications for cryoprecipitate administration include Hemophilia A, Von Willebrand’s disease, congenital Factor XIII deficiency, acute hypofibrinogenemia, and treating systemic issues in burns and traumatic shock.

Factor VIII Concentrate

The primary characteristics of this modern therapeutic extract define it as a specialized lyophilized product made from pooled plasma sources. It features an extended shelf life of 2 years at 2-8°C when kept under proper refrigeration. The clear medical indications for prescribing this purified factor product are exclusively for the management and treatment of haemophilia A.

Factor IX Concentrate

The chemical characteristics of this factor extract identify it as a lyophilized product made from pooled plasma. In its chemical composition, it contains factor II, VII, IX, X. It features a standard shelf life of 2 years at 2-8°C. The clinical indications for ordering this compound encompass the treatment of hereditary deficiency of factor II, VII, IX, X, managing Christmas disease, and treating patients with high factor VIII antibodies.

References:

• American Association of Blood Banks (AABB). Technical Manual. 20th ed. Bethesda, MD: AABB; 2020.

• Shaz BH, Christopher CD, Hillyer CD. Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects. 3rd ed. Elsevier; 2019.

• Hoffbrand AV, Steensma DP. Hoffbrand’s Essential Haematology. 8th ed. Wiley-Blackwell; 2020.

• World Health Organization. The Clinical Use of Blood: Handbook. Geneva: WHO; 2001.

• Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Burns LJ, Linch DC. Williams Hematology. 10th ed. McGraw-Hill Education; 2021.

• Silverstein LE, Cushing MM. Blood Components: Preparation, Indications, and Regulated Storage. New York: Medical Press; 2018.

• Blajchman MA, Goldman M. Guidelines for the Production, Control and Quality Assurance of Blood Components. Council of Europe Publishing; 2023.

• Simon TL, Jeffrey McCullough J, Snyder EL, Solheim BG, Stowell CP. Rossi’s Principles of Transfusion Medicine. 5th ed. Wiley-Blackwell; 2016.

• Murphy MF, Roberts DJ, Yazer MH. Practical Transfusion Medicine. 6th ed. Wiley-Blackwell; 2022.

• Harmening DM. Clinical Hematology and Fundamentals of Hemostasis. 6th ed. F.A. Davis Company; 2014.

• Mintz PD. Transfusion Therapy: Clinical Principles and Practice. 4th ed. AABB Press; 2011.

• Klein HG, Anstee DJ. Mollison’s Blood Transfusion in Clinical Medicine. 12th ed. Wiley-Black

FAQ:

• What determines blood component separation?

  Different specific gravities allow separation via centrifugation.

• What is the RBC specific gravity?

  The specific gravity ranges from 1.08 to 1.09.

• What is the function of RBCs?

  RBCs are responsible for oxygen transport to tissues.

• Which cells drive the immune response?

  WBCs, including neutrophils and lymphocytes, drive immune responses.

• What is the role of platelets?

  Platelets function in haemostasis and blood clotting.

• What are the main cellular components?

  They include red cell concentrate, granulocytes, and platelet concentrate.

• What is whole blood’s shelf life?

  It is 21 days in ACD/CPD and 35 days in CPDA1.

• At what temperature is PCV stored?

  PCV must be stored at 2-4°C.

• What are the indications for PCV?

  It is indicated for severe, hemolytic, hypoplastic, and aplastic anemias.

• What does 1 ml FFP provide?

  One milliliter of FFP provides 100% coagulation activity.

For Non-Medicos:
Overview

Blood components are prepared by separating whole blood into its individual components based on differences in specific gravity using centrifugation. This allows targeted therapy by transfusing only the required component rather than whole blood, improving efficacy and reducing transfusion-related risks. The major components include red cell concentrates, platelet concentrates, plasma, and plasma derivatives. Component therapy optimizes blood utilization and plays a vital role in modern transfusion medicine.

Symptoms

Blood components are used to manage patients with varied clinical presentations depending on the deficient element. Patients with anemia may present with pallor, fatigue, and breathlessness, while thrombocytopenia can cause petechiae, bruising, or active bleeding. Coagulation factor deficiencies may present with prolonged bleeding, hemarthrosis, or postoperative hemorrhage. Many patients receiving component therapy may be asymptomatic but require transfusion for surgical support or prophylaxis.

Causes

The need for specific blood components arises from selective deficiencies or clinical conditions. Red cell concentrates are required in anemia, blood loss, and chronic diseases. Platelet concentrates are indicated in thrombocytopenia, bone marrow suppression, chemotherapy, and bleeding disorders. Fresh frozen plasma is used for multiple coagulation factor deficiencies, liver disease, DIC, and reversal of anticoagulant effects. Cryoprecipitate and factor concentrates are used in inherited coagulation disorders such as hemophilia and von Willebrand disease. Plasma derivatives are prepared to replace specific proteins or clotting factors.

Risk Factors

Risk factors necessitating blood component therapy include trauma, major surgery, malignancy, bone marrow failure, chronic anemia, liver disease, inherited bleeding disorders, and severe infections. Patients requiring repeated transfusions, neonates, elderly individuals, and critically ill patients are at higher risk of transfusion-related complications. Improper component selection, storage errors, and incompatibility increase transfusion risks.

Prevention

Appropriate use of blood components helps prevent unnecessary transfusions and related complications. Strict adherence to transfusion guidelines, accurate patient evaluation, and component selection based on indication improve safety. Proper storage, handling, and compatibility testing reduce adverse reactions. Regular monitoring, hemovigilance programs, and rational component therapy ensure optimal patient outcomes and efficient use of blood resources.